Lessons learnt from the application of the HEcoPerMed guidance to three modelling case studies - Supplementary material

Appendix Table 1 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the NTRK case studyAppendix Table 2 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the ToxNav case studyAppendix Table 3 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the MODY case study附录表 1：关于个性化药物治疗经济评估统一与改进指南在 NTRK 案例研究中的应用建议 附录表 2：关于个性化药物治疗经济评估统一与改进指南在 ToxNav 案例研究中的应用建议 附录表 3：关于个性化药物治疗经济评估统一与改进指南在 MODY 案例研究中的应用建议